Dr. Millonig, a director in the Biotechnology/Chemical Group, has significant experience developing and analyzing complex multi-patent portfolios for marketed pharmaceutical products. His approach to resolving legal issues revolves around reaching the solution that best meets the client's business needs. Dr. Millonig counsels clients in various intellectual property matters including patent validity and infringement analysis, freedom to operate, patentability investigations and FDA/ANDA practice. He is versed in the interplay between FDA regulations and patent law and has successfully co-counseled on major litigation involving patent challenges.
Specifically, Dr. Millonig has been involved in developing strategy for defending challenges to Barr Laboratories' patents on fexofenidine, alendronate, raloxifine and extended release niacin to name a few.
More Legal and Business Bylines From Robert C. Millonig, Jr., Ph.D.
